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improves the odds of a good stroke outcome when delivered within 4.5 hours of acute ischaemic stroke. Alteplase also increases the risk of intracerebral haemorrhage, but the factors determining the proportional and absolute risks are uncertain. Methods: We used data from the Stroke Thrombolysis Trialists' (STT) metaanalysis of individual patient data from 9 randomised trials of alteplase versus placebo (or open control) involving 6,756 patients. We prespecified assessment of 3 definitions of intracerebral haemorrhage: type 2 parenchymal haemorrhage (PH-2) within 7 days; SITS-MOST haemorrhage within 24-36 hours (PH-2 with at least 4 point deterioration in NIHSS); and fatal intracerebral haemorrhage within 7 days. We used logistic regression, stratified by trial, to model the log odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity. Exploratory analyses assessed mortality after intracerebral haemorrhage and examined the absolute risks of intracerebral haemorrhage in the context of functional outcome at 90-180 days. Findings: Alteplase increased the odds of PH-2 haemorrhage (231/3391 [ . However defined, the proportional increase in intracerebral haemorrhage was similar irrespective of treatment delay, age or baseline stroke severity, but the absolute excess risk of intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral haemorrhage the absolute excess risk ranged from 1.5% (95% CI 0.8-2.6%) for strokes with NIHSS 0-4 to 3.7% (95% CI 2.1-6.3%) for NIHSS ≥22 (trend p=0.01). For those treated within 4.5 hours, the absolute increase in the proportion (6.8%) achieving a modified Rankin score of 0 or 1 (excellent outcome) exceeded the absolute increase in risk of fatal intracerebral haemorrhage (2.2%) and the increased risk of any death within 90 days (0.9%). Interpretation: Among patients treated with alteplase the net outcome is predicted both by time to treatment (with faster time increasing the proportion achieving an excellent outcome) and stroke severity (with more severe stroke increasing the absolute risk of intracerebral haemorrhage). Although, on average, within 4.5 hours of stroke, the probability of achieving an excellent outcome clearly exceeds the risk of death, early treatment is especially important for those with severe strokes.
Introduction 1
The Stroke Thrombolysis Trialists' (STT) Collaboration has previously shown, in a meta-analysis of 2 individual participant data from 9 trials of alteplase versus placebo (or open control), that alteplase 3 significantly improves the odds of an excellent outcome (i.e., a modified Rankin score [mRS] of 0 or 4 1) when delivered within 4.5 hours of the onset of ischaemic stroke. 1 However, alteplase increases 5 the risk of intracerebral haemorrhage within 48 hours of administration, 1 and variations in the 6 absolute risks of such haemorrhage according to clinical presentation (eg, stroke severity) may 7 influence the longer term outcome. Recent commentaries have drawn attention to a lack of reliable 8 information about the hazards of alteplase and how they relate to benefits among different groups 9 of patients, particularly those presenting more than 3 hours after stroke onset. 2, 3 In the UK, the 10
Medicines and Healthcare Products Regulatory Agency (MHRA) expert working group considered, in 11 strict confidence, these analyses from the STT Collaboration on the benefits and risks of alteplase as 12 part of its review of the market authorisation for alteplase in acute ischaemic stroke. 4 13 14 Since there are strong inter-relationships between prognostic variables among the trials included in 15 the STT database (for example, patients treated earlier tended to be older and to have had more 16 severe strokes), an assessment of benefit and harm can only be performed reliably using 17 multivariable models applied to individual participant data. The STT's published protocol 5 outlined a 18 range of secondary analyses that were to be conducted in addition to the main analysis. 1 The aim of 19 the present report is to describe the results of secondary analyses assessing the proportional and 20 absolute effects of alteplase on the risk of intracerebral haemorrhage and of mortality in different 21 types of patients. We also explore how such variations might influence the net effects of alteplase by 22 90-180 days after stroke. 
Study design 26
The methods of the Stroke Thrombolysis Trialists' (STT) Collaboration have been described in detail 27 in the published protocol 5 and in the main report of the primary analysis. 1 Briefly, we sought 28 individual participant data from all completed randomised phase 3 trials of intravenous alteplase in 29 acute ischaemic stroke. Since a systematic review of trials of thrombolysis had been updated in 2013 30 6 we identified potentially eligible trials from that review and by enquiry among active trialists and 31 the manufacturer of alteplase used in all participating trials (Boehringer Ingelheim, Ingelheim, 32
Germany). 5 We analysed participants in the group to which they were randomly allocated ('intention 33 to treat'). 34
Outcomes 35
The main outcome of interest in the current analysis was intracerebral haemorrhage, which was 36 defined in three ways: 37 (i) parenchymal haemorrhage type 2 (PH-2) by 7 days after randomisation: defined as dense 38 blood clot(s) exceeding 30% of the infarct volume with significant space-occupying effect 39 seen on brain imaging, whether within or remote from the infarct. 7 For patients from IST-3, 8 40 in which PH-2 defined solely on radiological findings was not a pre-specified secondary 41 outcome, we approximated it by a report from the IST-3 blinded CT-reading panel of 42 'significant brain parenchymal haemorrhage, local or remote from the infarct, or significant 43 diffuse haemorrhagic transformation of an infarct on brain imaging'; 44 (ii) Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) 45 haemorrhage 9 defined as PH-2 on imaging with an increase of 4 NIHSS points or more from 46 baseline (or the lowest point in the first 24 hours) or that led to death within 36 hours of 47 treatment. In the third international stroke trial (IST-3), we approximated the SITS-MOST 48 definition by the occurrence within 24 hours of 'clinically significant deterioration or death, 49 together with evidence of either significant brain parenchymal haemorrhage (local or distant 50 from the infarct) or significant haemorrhagic transformation of an infarct on brain imaging 51 which, in the judgement of the blinded adjudication panel, was likely to have worsened mass 52 effect or contributed to the burden of brain damage'; and 53 (iii) fatal intracerebral haemorrhage, defined as PH-2 (or its approximation in IST-3) 54 confirmed by imaging (or autopsy) and death within 7 days of randomisation. 55 56 3
The timing of brain imaging to detect intracerebral haemorrhage varied slightly across the 57 participating trials. The protocol of each trial mandated imaging at approximately 24 hours post-58 randomisation and additional brain imaging if neurological deterioration occurred. Further routine 59 brain imaging was performed at 3-5 days in the Echoplanar Imaging Thrombolytic Evaluation Trial 60 (EPITHET), 10 at 1 week in National Institutes of Neurological Diseases and Stroke (NINDS) A and B 11 61 and in European Cooperative Acute Stroke Study (ECASS) I, II, and III; 7, 12, 13 , and at 23-37 days in 62
Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke (ATLANTIS) A and 63 B. 14,15 64 65
Analyses of the effect of alteplase on death from all causes within 90 days, both overall and when 66 separated by period of follow-up and treatment delay, have been published previously. 1 In post-hoc 67 analyses of mortality for the current analysis, we subclassified deaths as: "deaths preceded by 68 clinically significant intracerebral haemorrhage" (defined as fatal ICH within 7 days or death 69
following SITS-MOST haemorrhage), and all other deaths. 70
71
We analysed the modified Rankin score (mRS) to define stroke outcome at 3-6 months. We defined 72 an 'excellent' stroke outcome as mRS of 0-1 (ie, symptom-free or residual symptoms with no loss of 73 activity), and a very poor stroke outcome as mRS of 5-6 (i.e. bed-bound or dead) at 3-6 months. In 74 IST-3, mRS was reported at 6 rather than 3 months. Therefore, for consistency between the 75 previously published analyses of 90-day mortality and the odds ratio estimates for mRS 0-5 vs 6 in 76 the current analysis, we made the simplifying assumption that IST-3 patients who died between 91 77 days and 6 months (125 [4.1%] IST-3 participants) had an mRS of 5 at 90 days. 1 78 79
Statistical analysis 80
We used logistic regression, stratified by trial, to model the common linear dependence of the log 81 odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, baseline stroke 82 severity (National Institutes of Health Stroke Scale [NIHSS] ) and interactions between allocation to 83 alteplase and each of these other baseline covariates. Alternative hierarchical models that allowed 84 for random effects to operate at the trial level gave virtually identical results. Treatment delay, age 85
and stroke severity were all handled as linear variables. Analyses that considered quadratic risk-86 relationships for stroke severity were not informative over the models that simply considered a 87 linear term, and are therefore not reported. In addition to such 'continuous' analyses, regression 88 models that handled each baseline covariate in pre-defined categories of treatment delay (≤3.0 89 hours, >3 to ≤4.5 hours, >4.5 hours), age (≤80, >80 years) and stroke severity (NIHSS ≤4, 5-10, 11-15, 90 16-21, ≥22) were also employed. Missing 6 month modified Rankin data in IST-3 were imputed from 91 seven-day assessments using an algorithm that was found to work well among patients who had 92 both measurements. 5 Assessment of whether treatment delay, age, stroke severity or trial modified 93 (individually or jointly) the overall effect of alteplase on particular outcomes was based on the 94 statistical significance of the relevant treatment interactions using likelihood ratio tests (i.e. through 95 comparison of minus twice the log-likelihood statistic between appropriate "nested" models). Trial-96 by treatment interactions were used to assess whether there were important differences in the odds 97 of intracerebral haemorrhage with alteplase between the 9 trials, and between IST-3 (with open 98 control) and all other (placebo-controlled) trials combined. 99 100 Kaplan-Meier cumulative mortality curves during the first 90 days were calculated for patients 101 allocated alteplase and patients allocated control (crudely pooling across all trials). Subsequently, 102 trial-stratified Cox regression was used to estimate the average mortality hazard ratio within 90 days 103 for 'deaths preceded by clinically significant intracerebral haemorrhage' and for all other deaths, 104
with the time to event/censoring for both outcomes set as the earliest of day 90 or the date of 105 death. 106 107 Stroke severity and treatment delay are both important determinants of stroke outcome for patients 108
given alteplase. However, as previously reported, stroke severity and treatment delay were 109 correlated in the included trials. 1 Therefore, to prevent treatment delay from confounding the 110 observed mRS distribution when treated patients were subdivided by their baseline stroke severity 111 (NIHSS ≤4; 5-10; 11-15; 16-21 and ≥22), we compared, for each baseline NIHSS group, the observed 112 mRS distribution for control patients with the expected distribution if given alteplase within 3 or 113 within 4.5 hours. This expected distribution was obtained by applying the overall odds ratios for each 114 mRS dichotomy (ie, mRS 0 vs 1-6, mRS 0-1 vs 2-6, etc.) within a given time window (≤4.5 hours, <3 115 hours or 3-4.5 hours) to the observed mRS distribution at 3-6 months among control-allocated 116 patients. Similarly, the estimates of absolute excess risk subdivided by a given characteristic 117 (treatment delay, age or stroke severity) were obtained by applying the overall odds ratio estimates 118 (and their confidence limits) to the control rates that would have been expected for that subgroup 119 had average levels of the other two characteristics applied. 120 121 5 122
All estimates of treatment effect are provided with their 95% confidence intervals with p-values 123 considered conventionally statistically significant, without allowance for multiple testing, at the 5% 124 significance level. Analyses were done with SAS version 9.3 (SAS Institute, Cary) and R version 2.11.1 125
Results 133
Data were available from 6756 participants in 9 trials of intravenous alteplase versus control 134 (webtable 1). Baseline data on treatment delay, age and baseline NIHSS were complete for almost all 135 participants (6602/6756, 98%). Individual participant data were sought from an additional 5 trials 16-136 20 involving 270 participants, which reported a total of 18 patients with intracerebral haemorrhage 137 (11 alteplase versus 7 control), but were either not available or, in one case, 18 For each type of intracerebral haemorrhage, the proportional effects of alteplase were similar 154 irrespective of time to treatment, age or stroke severity (webfigures 2-4; p-values for interaction all 155 >0.05). The estimated absolute excess risks were similar irrespective of time to treatment and age, 7 but there was a trend towards larger absolute excess risks with increasing stroke severity for PH-2 157 haemorrhage (p<0.0001; webfigure 5), fatal intracerebral haemorrhage (p=0.0002; webfigure 6) and 158 SITS-MOST haemorrhage (p=0.0101; figure 2 ). For SITS-MOST intracerebral haemorrhages (ie, 159 clinically significant bleeds in which there was both radiological evidence of bleeding and worsening 160 symptoms within 24-36 hours after treatment), the absolute excess risk over control increased from 161 1.5% (95% CI 0.8-2.6%) among those with mild strokes (baseline NIHSS 0-4) to 3.7% (95% CI 2.1-162 6.3%) in patients with NIHSS ≥22 (figure 2). 163
Cause of death was not widely available in participating trials, but we conducted exploratory 164 analyses to assess the 90-day risks of 'death preceded by clinically significant intracerebral 165 haemorrhage' and of all other deaths. Among all trial participants, allocation to alteplase was 166 associated with a significant increase in the risk of a death preceded by clinically significant 167 3). An analysis that defined clinically significant haemorrhage by the radiological appearance of a 171 PH2 haemorrhage, rather than by the SITS-MOST definition, gave similar results (webfigure 8). 172
173
Since the estimated absolute excess risk of intracerebral haemorrhage increased incrementally 174 within the 5 pre-specified categories of stroke severity, we assessed the impact of this trend on the 175 expected distribution of mRS scores at 90 days among all patients treated within 4.5 hours (on 176 average, at 3 hours and 20 minutes) by applying the odds ratio for each mRS transition to the control 177 population (figure 4 and 5). Among patients with the mildest strokes (NIHSS 0-4), alteplase would be 178 expected to result in an absolute increase in excellent outcome of 8.0% (95% CI 4.5-11.1), and to 179 reduce the absolute risk of very poor outcome by 0.1% (95% CI -0.6-0.8; 0.3% reduction in severe 180 disability [mRS 5] and 0.2% excess of death). For the most severe strokes (NIHSS ≥22), the 181 corresponding amounts were a 1.0% (95% CI 0.5-1.5) absolute increase in excellent outcome and a 182 0.6% reduction in very poor outcome (95% CI -2.3-4.1; 2.8% reduction in severe disability and 2.1% 183 excess of death). 184
Discussion 185
Within the 9 trials studied, alteplase resulted in approximately 6 to 7 times the odds of intracerebral 186 haemorrhage within the first 7 days, which was similar irrespective of treatment delay, age and 187 stroke severity. In these trials the underlying risk of intracerebral haemorrhage without alteplase 188 increased with stroke severity, which is consistent with a systematic review of 55 observational 189 studies in which each 1 point increment in the NIHSS was associated with an 8% (95% CI 6-11%) 190 increase in the odds of intracerebral haemorrhage (p<0.001). 21 In the absence of heterogeneity of 191 the odds ratio for haemorrhage, therefore, the absolute excess risk of intracerebral haemorrhage 192 was higher among those with more severe strokes. Overall, among all patients, alteplase resulted in 193 a 2.3% absolute excess of fatal intracerebral haemorrhage during the first week ( Figure 1 ). After the 194 first week, deaths preceded by ICH remained elevated among those allocated alteplase ( Figure 3 hours, alteplase is associated with an early hazard due to intracerebral haemorrhage but a later 201 benefit in terms of less disability, and this study raises the hypothesis that there is a lower risk of 202 death among those not experiencing an intracerebral haemorrhage. This pattern is analogous to 203 many surgical procedures, eg carotid endarterectomy, where there is an early surgical hazard 204 followed by a later survival benefit in selected patients 22, 23 and the balance of hazard and benefit 205 among particular types of patients determines their net clinical outcome. 206
207
The net effects of alteplase among particular types of patients are best represented by the predicted 208 shift in the distribution of modified Rankin Scores among patients allocated to alteplase and control. 209
Our previous analyses indicated that the benefits of alteplase diminish with increasing treatment 210 delay, whilst the present analyses indicate that the absolute excess risk of intracerebral 211 haemorrhage increases with stroke severity. Our exploratory analyses suggest that these two 212 variables help determine the net effects of alteplase in particular patients. In particular, they may 213 help to explain the observation in our previous report 1 that there was a non-significant trend 214 towards a larger relative increase in 90 day mortality among those treated later. Although there 215
were limited data in the 3-4.5 hour group, it may be hypothesised that the observed patterns are 216 due to the shifting balance between (i) an early increase in mortality from intracerebral 217 haemorrhage (which is of similar magnitude irrespective of delay) and (ii) reduced mortality due to 218 salvaged brain tissue among those treated early, with the magnitude of this benefit diminishing as 219 delay increases (ie, 'time is brain'). 220
221
There is a need for improved representations of the benefits and risks of alteplase, building on those 222 developed previously [24] [25] [26] [27] , to better equip clinicians in discussions with patients and their family 223 members. Recent trials have demonstrated that intra-arterial thrombectomy in addition to intravenous 236 thrombolysis leads to improved outcomes [28] [29] [30] [31] [32] among those with large artery ischaemic stroke and 237 documented proximal arterial occlusion, which may help to improve the ratio of benefit to risk by 238 magnifying benefit through improved salvage of brain tissue. Alternatively, it may be possible to 239 improve this ratio by reducing the risk of intracerebral haemorrhage with intravenous thrombolytic 240 therapy, for example, by the use of tenecteplase as an alternative to alteplase 33, 34 , use of a lower 241 dose of alteplase (0.6mg/kg), 35 or by targeting thrombolysis based on neuroimaging appearances. 31 
243
Although our analyses provide a general guide to the effects of alteplase in different types of 244 patients, there are a number of potential limitations: First, and most importantly, despite having 245 access to individual participant data from 9 trials in almost 7000 patients with acute ischaemic 246 stroke, there were relatively small numbers of outcomes with which to examine treatment effects in 247 different patient subgroups. 32 Whilst recognising that there is a need to provide better information 248 for doctors and patients, it is important that treatment decisions take account both of statistical 249 uncertainty and of the possibility that different patients and their families may reach different 250 decisions when presented with the same data on expected outcomes. The second limitation was 251 that the methods employed by the Third International Stroke Trial (IST-3) differed in several respects 252 to the other trials. It lacked a placebo control, raising the potential of biased reporting if there was a 253 greater tendency to investigate possible intracerebral haemorrhage in the alteplase arm. However, 254 alteplase increased the odds of intracerebral haemorrhage to a similar extent in IST-3 and in other 255 trials (webfigure 1), suggesting that any bias due to the open nature of IST3 was small. The IST3 trial 256 also did not record PH-2 haemorrhages or SITS-MOST haemorrhages, but defined equivalent 257 categories. In the future, any such limitations caused by different symptomatic haemorrhage 258 definitions and classifications may be mitigated by the use of the recent Heidelberg classification of 259 intracerebral bleeding events. 39 
261
A third limitation was that we did not have cause of death available, but could only examine the 262 effects of alteplase on deaths that followed a haemorrhage. Our data strongly suggest, however, 263 that most early deaths following a PH2 haemorrhage were likely to be due to the haemorrhage. In 264 particular, the increased risk of death from any cause by 7 days (absolute excess 2.2%) 1 is virtually 265 identical to the increased risk of those deaths that followed a PH2 haemorrhage (2.3%) (Figure 1) . In 266 addition, death preceded by clinically significant haemorrhage remained elevated after the first 267
week (Figure 3 ). The most likely explanation for these large mortality differences is that 268 haemorrhage led to death in almost all such cases (either directly, or after withdrawal of medical 269 intervention), since the alternative explanation -that alteplase-allocated patients were at least 7 270 times more likely than control-allocated patients to die from causes unrelated to the bleed -seems 271 highly implausible given their similar prognostic scores at randomization and the lack of any other 272 known hazard of alteplase. 273
274
Finally, we were limited in the extent to which we could evaluate the effect of other potential risk 275 factors, such as blood glucose and blood pressure control, that have previously been associated with 276 increased bleeding risk after alteplase administration, and nor could we assess the effects of 277 alteplase on less severe intracerebral haemorrhage since the requisite data were not consistently 278 
Figure legends

Research in Context 363
Evidence before this study 364 Meta-analyses have previously shown that alteplase increases the risk of intracerebral haemorrhage, 365 but the extent to which the absolute excess risk differs by haemorrhage type, stroke severity, age, or 366 treatment delay was uncertain, as was the balance between the risk of intracerebral haemorrhage 367 and treatment benefit in different patients. We used individual participant data from 9 trials of 368 alteplase versus control in the Stroke Thrombolysis Trialists' Collaboration to provide meta-analyses 369 of the available evidence. 370
Added value of this study 371
This study provides estimates of symptomatic intracerebral haemorrhage risk, and benefits due to 372 alteplase, in patients grouped by stroke severity, age and treatment delay. With the individual 373 participant data, we were able to adjust for complex inter-correlations between variables to produce 374 reliable estimates of absolute treatment effects. 375
Implications of all the available evidence 376
The absolute benefits of alteplase decline with treatment delay, and the absolute harms due to 377 alteplase (from intracranial haemorrhage) increase with stroke severity. When delivered within 4.5 378 hours, the proportion of patients experiencing a good outcome exceeds those dying from 379 intracranial haemorrhage. However, because the risk of haemorrhage is highest in those with the 380 most severe stroke, prompt treatment of these patients is especially important. These absolute risk 381 estimates will be useful to communicate the effects of alteplase to patients, families and clinicians. 382 * For each of the three baseline characteristics shown, the odds ratio subgroup estimates shown are derived from a single trial−stratified logistic regression model which allows for separate estimation of the OR in each of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics). The overall effect in all patients (indicated by the open diamond) is the trial−stratified logistic regression estimate adjusted only for treatment allocation.
The absolute excess risk (and its 95% CI) for each subgroup is estimated by applying the odds ratio seen among all randomised patients (or its confidence limits) to the average expected risk among control−allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for trial, treatment allocation, the subgroup of interest and average levels of the other two baseline characteristics).X Expected outcome if GIVEN alteplase within 3 hrsX XX X X X XExpected outcome if GIVEN alteplase within 3−4.5 hrs XX XX X X X X mRS: 0−1 2 3 4 5 6
('X' represents deaths within 7 days and following a PH2 haemorrhage)Webmaterial: What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials 
Webfigure 1: Effect of alteplase on intracerebral haemorrhage in each trial
Where estimable, individual trial estimates above correspond to the simple odds ratio and its 95% confidence interval. The summary diamonds, and their 95% CIs, are derived from trial−stratified logistic regression models (which allow trials with zero events in the control arm to contribute information 
Webfigure 2: Treatment−modifying effects of time to treatment, age and stroke severity on parenchymal haemorrhage type 2 within 7 days
The solid line on each plot shows how the estimated odds ratio associated with allocation to alteplase varies with, respectively, time, age and baseline NIHSS, so its slope provides a test for interaction between that characteristic and allocation to alteplase. Each panel is adjusted for treatment delay, age, and baseline NIHSS (as linear main effects), and all three treatment−interaction terms (ie, all three panels derive from the same regression model).
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.26 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test). 
Webfigure 3: Treatment−modifying effects of time to treatment, age and stroke severity on SITS−MOST intracerebral haemorrhage at 24−36 hours
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.94 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test). 
Webfigure 4: Treatment−modifying effects of time to treatment, age and stroke severity on fatal intracerebral haemorrhage within 7 days
The odds ratio in each panel corresponds to patients with AVERAGE levels of the other 2 baseline characteristics. The OR for alteplase was 6.63 at the mean values of age (71 years), NIHSS (12 points) and time to treatment (4 hours). The significance of each interaction, as well as the global test of all interactions, is tested by comparing the change in deviance between two nested models that differ only by the interaction term(s) (ie, the likelihood ratio test). 
